Get the Stockscreener App
4.36
1.36%
-0.06
Clene Inc stock is traded at $4.36, with a volume of 50,418.
It is down -1.36% in the last 24 hours and down -25.98% over the past month.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements).
See More
Previous Close:
$4.42
Open:
$4.4
24h Volume:
50,418
Relative Volume:
0.63
Market Cap:
$36.80M
Revenue:
$442.00K
Net Income/Loss:
$-30.46M
P/E Ratio:
-0.9776
EPS:
-4.46
Net Cash Flow:
$-27.47M
1W Performance:
-2.90%
1M Performance:
-25.98%
6M Performance:
-3.11%
1Y Performance:
-50.45%
1-Day Range:
$4.15
$4.40
1-Week Range:
$4.15
$4.7099
52-Week Range:
$3.8181
$10.65
Clene Inc Stock (CLNN) Company Profile
Name
Clene Inc
Sector
Industry
Phone
801-676-9695
Address
6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY
Compare CLNN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLNN
Clene Inc
|
4.31 | 36.80M | 442.00K | -30.46M | -27.47M | -4.46 |
|
KHC
Kraft Heinz Co
|
29.06 | 35.23B | 26.13B | 1.37B | 3.00B | 1.11 |
|
GIS
General Mills Inc
|
58.80 | 32.65B | 19.90B | 2.60B | 2.80B | 4.60 |
|
K
Kellanova Co
|
82.22 | 28.11B | 12.80B | 1.01B | 927.00M | 2.91 |
|
MKC
Mccormick Co Inc
|
77.69 | 20.73B | 6.68B | 792.60M | 774.40M | 2.94 |
|
HRL
Hormel Foods Corp
|
28.85 | 16.02B | 11.92B | 805.04M | 1.01B | 1.46 |
Clene Inc Stock (CLNN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-04-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-18-22 | Initiated | H.C. Wainwright | Buy |
| May-02-22 | Initiated | Canaccord Genuity | Buy |
| Sep-28-21 | Initiated | Oppenheimer | Outperform |
Clene Inc Stock (CLNN) Latest News
Clene Inc. secures additional NIH grant funds for ALS therapy - MSN
Promising Nanotechnology Stocks To Keep An Eye OnJanuary 31st - MarketBeat
Nanotechnology Stocks To Keep An Eye OnFebruary 03rd - MarketBeat
Nanotechnology Stocks To Follow NowFebruary 01st - MarketBeat
Best Nanotechnology Stocks To Follow TodayJanuary 30th - MarketBeat
Clene Inc. secures additional NIH grant funds for ALS therapy By Investing.com - Investing.com UK
Clene files to sell 1.15M shares of common stock by selling shareholders - MSN
Clene (CLNN) Stock Price, News & Analysis - MarketBeat
IBN Coverage: Clene (NASDAQ: CLNN) Paves Cash Runway to Advance CNM-Au8(R) for ALS - Nasdaq
Clene Secures $10 Million Debt Facility to Advance ALS Drug Development - Citybuzz
Clene (NASDAQ: CLNN) Paves Cash Runway To Advance CNM-Au8(R) For ALS - Barchart
3 US Growth Stocks With High Insider Ownership - Yahoo Finance
IBN Coverage: Clene (NASDAQ: CLNN) Receives FDA Roadmap on Potential Accelerated Pathway for CNM-Au8(R) - Yahoo Finance
Clene Receives FDA Guidance on Potential Accelerated Approval Pathway for ALS Drug CNM-Au8 - Citybuzz
Clene (NASDAQ: CLNN) Receives FDA Roadmap on Potential Accelerated Pathway for CNM-Au8(R) - The Globe and Mail
Clene Secures $10M Debt Facility to Enhance Position - TipRanks
Clene Secures $10 Million Debt Facility to Advance ALS and Neurodegenerative Disease Treatments - Citybuzz
IBN Coverage: Clene (NASDAQ: CLNN) Secures $10M Debt Facility to Advance Neurodegenerative Disease Treatments - Yahoo Finance
Clene Improves Cash Position and Runway by Securing New Debt Facility to Pay Off Existing Senior Loan - The Manila Times
Real-World Evidence Helps Open Accelerated Approval Pathway For Neurodegeneration Therapies - News & Insights
Clene Inc. Provides Update on Corporate Presentation and ALS Clinical Trials - Defense World
IBN Coverage: Clene (NASDAQ: CLNN) Advances CNM-Au8 in ALS With FDA Guidance on Accelerated Approval Pathway - Yahoo Finance
FDA outlines steps to consider accelerated approval of CNM-Au8 - ALS News Today
Clene Receives FDA Guidance on Accelerated Approval Path for ALS Treatment CNM-Au8 - Citybuzz
Clene Gains FDA Support for ALS Treatment Approval - TipRanks
FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS - The Manila Times
FDA Opens Accelerated Approval Path for Clene's Breakthrough ALS Treatment After 78% Survival Benefit - StockTitan
Clene (NASDAQ:CLNN) Given New $84.00 Price Target at Benchmark - Defense World
Clene shares hold Buy rating as analyst sees FDA decision impacting time to market - Investing.com
Roth Capital Has Bearish Forecast for Clene FY2024 Earnings - Defense World
Clene (NASDAQ:CLNN) Price Target Lowered to $83.00 at Canaccord Genuity Group - Defense World
HC Wainwright Reaffirms Buy Rating for Clene (NASDAQ:CLNN) - Defense World
AWM Investment Company, Inc. Expands Stake in Clene Inc - GuruFocus.com
Clene price target lowered to $83 from $86 at Canaccord - Yahoo Finance
ARMISTICE CAPITAL, LLC Acquires New Stake in Clene Inc - GuruFocus.com
Certain Warrants of Clene Inc. are subject to a Lock-Up Agreement Ending on 15-NOV-2024. - Marketscreener.com
Clene Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Canaccord cuts Clene stock target, holds buy rating on FDA meeting - Investing.com UK
Clene Inc (CLNN) Q3 2024 Earnings: EPS of -$1.22 Beats Estimates, Revenue at $0.087 Million Misses Expectations - GuruFocus.com
Clene Inc. (CLNN) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Clene Announces Q3 2024 Results and ALS Drug Progress - TipRanks
Clene Reports Third Quarter 2024 Financial Results and Recent Operating Highlights - The Manila Times
(CLNN) Technical Data - Stock Traders Daily
Clene to Meet with FDA Leadership to Discuss CNM-Au8 Biomarker for ALS Treatment - Vancity Buzz
IBN Coverage: Clene (NASDAQ: CLNN) Set to Discuss Lead Candidate Biomarker With FDA Leadership - Yahoo Finance
Clene Unveils Phase 3 Trial Design at NEALS - TipRanks
Clene Showcases Progress on CNM-Au8 for Neurodegenerative Diseases at Investor Conferences - Vancity Buzz
IBN Coverage: Clene (NASDAQ: CLNN) Presents Lead Candidate CNM-Au8(R) Updates at Investor Conferences - Yahoo Finance
Clene Inc (CLNN-Q) QuotePress Release - The Globe and Mail
(CLNN) Trading Report - Stock Traders Daily
IBN Coverage: Clene (NASDAQ: CLNN) Closes $7.3M Registered Direct Offering and Concurrent Private Placements - Yahoo Finance
Clene Inc Stock (CLNN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Clene Inc Stock (CLNN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mortenson Mark | Chief Science Officer |
Sep 30 '24 |
Buy |
4.75 |
20,512 |
97,432 |
28,949 |
| Etherington Robert Dee | Chief Executive Officer |
Sep 30 '24 |
Buy |
4.75 |
10,000 |
47,500 |
40,149 |
| Etherington Robert Dee | Chief Executive Officer |
Jul 29 '24 |
Option Exercise |
3.00 |
27,320 |
81,960 |
30,149 |
| General Resonance LLC | 10% Owner |
Apr 30 '24 |
Sale |
0.42 |
13,000 |
5,416 |
15,326,712 |
| General Resonance LLC | 10% Owner |
May 01 '24 |
Sale |
0.40 |
13,000 |
5,148 |
15,313,712 |
| General Resonance LLC | 10% Owner |
Apr 24 '24 |
Sale |
0.33 |
10,000 |
3,278 |
15,349,712 |
| General Resonance LLC | 10% Owner |
Apr 09 '24 |
Sale |
0.39 |
22,500 |
8,674 |
15,428,212 |
0.91%
3.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):